Personalized cancer vaccine shows promise, experts weigh in

Moderna developed a personalized cancer vaccine with Merck and tested it in combination with Keytruda, an immunotherapy treatment for melanoma. According to Moderna President Stephen Hoge, if regulators approve the vaccine, thousands of patients who have had high-risk melanoma tumors removed could benefit from it as early as next year.